What Accutest does

Accutest Research Laboratories Pvt. Ltd. is a privately held Indian contract research organization founded in 1998 and headquartered in Mumbai. The company delivers fee-for-service clinical research to global pharmaceutical and biotechnology sponsors, with a service stack spanning bioavailability/bioequivalence (BA/BE) studies, Phase II–IV late-phase clinical trials, biologics and biosimilar characterization, bioanalytical testing, and clinical data management/biostatistics/real-world evidence analytics. Accutest serves both primary customer segments — pharma companies executing generic-drug and novel-drug BA/BE programs, and biotech companies running biosimilar comparability and immunogenicity work — through direct enterprise sales and quote-based, project-specific contracts. The firm is the first independent Indian CRO and has operated for 27+ years without disclosed external institutional capital.

The company's technical footprint is anchored by two dedicated laboratories. The Bioanalytical Laboratory operates 21 LC-MS/MS systems (AB Sciex API 6500+, 5500, 4500, 4000 and Waters Xevo TQ-XS, TQS, TQ) supporting 1,000+ validated analytical methods for multi-analyte, chiral, and endogenous-substance quantification. The Biologics Laboratory houses flow cytometry (Attune), NGC chromatography (Bio-Rad NGC Discover Quest 10 Plus), Nexera X2 UPLC/HPLC, and ICP-OES/ICP-MS for cell-based assays, protein characterization, and immunogenicity testing. Clinical operations run from 150,000+ sq. ft. of infrastructure across Mumbai and Vadodara with 262 clinical beds and a 45,000+ healthy volunteer database. IT is built on Nutanix hyper-converged infrastructure, secured by Fortinet next-generation firewalls and SentinelOne AI endpoint protection, with 21 CFR Part 11 and GAMP5 validation across GxP systems. Accutest has cleared 140+ regulatory inspections from DCGI, USFDA, MHRA, WHO, EMA, ANVISA, NPRA, Thai FDA, MCC, and GCC.

The company is led by Chairman D M Reddy (38+ years of cross-industry leadership), President & CEO Dr. Nirav Gandhi (MD Pharmacology, ex-Lambda, ex-Intas, ex-Cipla), CFO P. R. Raman, and a senior team that in August 2025 added Ravindra Gandham as VP Global Business Development (ex-Cliantha, ex-Syneos Health). The GTM motion is direct enterprise sales led by senior leadership targeting global pharma and biotech sponsors, supported by corporate presentations, webinars, scientific publications, and a corporate website. Accutest reports a 98% study accuracy and 95% client satisfaction rate.

Name

Accutest

Legal name

Accutest Research Laboratories Pvt. Ltd.

Website

https://accutestglobal.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Accutest Research Laboratories is a private Indian CRO founded in 1998 providing BA/BE studies, Phase II-IV clinical trials, bioanalytical testing, and biologics characterization services to global pharmaceutical and biotechnology sponsors. The Mumbai-headquartered firm operates 21 LC-MS/MS systems and 262-bed clinical facilities.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Real-World Evidence (RWE), HEOR & Epidemiology CROs (HLAGAAAK), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Contract research services
• Bioequivalence studies
• Clinical trials
• Bioanalytical testing
• Biologics characterization

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Contract Research Services: B2B contract research organization providing fee-for-service CRO services including BA/BE studies, clinical trials, and bioanalytical testing to pharmaceutical and biotech companies worldwide. Revenue generated through project-based contracts for drug development studies.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Accutest is an independent Indian Contract Research Organization (CRO) providing bioequivalence/bioavailability (BA/BE) studies, late-phase (Phase II-IV) clinical trials, bioanalytical laboratory services, and biologics/biosimilar characterization for global pharmaceutical and biotech sponsors. Services are delivered through 262-bed clinical facilities, a bioanalytical lab with 21 LC-MS/MS systems, and a dedicated biologics lab with flow cytometry, NGC chromatography, and UPLC/HPLC capabilities, generating regulatory-compliant data accepted by DCGI, USFDA, EMA, WHO, ANVISA, MHRA, and other authorities.

Product overview

Accutest is a platform of integrated clinical research services organized around four core pillars: BA/BE Studies (the foundational service), Late Phase Clinical Trials (Phase II–IV), Biologics Services, and CDM, Biostatistics & Real World Evidence. These services are underpinned by two dedicated laboratory divisions — the Bioanalytical Laboratory (21 LC MS/MS systems, 1,000+ validated methods, chiral and multi-analyte expertise) and the Biologics Laboratory (flow cytometry, NGC chromatography, UPLC/HPLC, ICP-OES/MS for cell biology, protein characterization, and immunogenicity). IT Infrastructure & Digital Systems provide validated GxP computing, cybersecurity, and electronic document management. Clinical Facilities in Mumbai and Vadodara (150,000+ sq. ft., 262 beds, 45,000+ volunteer database) provide the operational capacity for large-scale study execution. Together these modules function as a unified CRO service offering with end-to-end capabilities from early-phase bioequivalence through late-phase clinical trials and biologics characterization.

Differentiator

Problem solved

Functional benefit

Products and services

• BA/BE Studies Bioavailability and bioequivalence studies for generic and novel drug products including single-dose, multiple-dose, replicate, food-effect, and specialized population studies, generating data accepted by DCGI, USFDA, EMA, WHO, ANVISA, and other global regulatory authorities. Targeted at pharmaceutical sponsors requiring regulatory-grade bioequivalence data for global drug approvals.
• Late Phase (Phase II-IV) Clinical Trials Phase II through Phase IV clinical development services for small and large molecules across therapeutic areas including Oncology, Cardiovascular, Psychiatry, Neurology, Dermatology, and Infectious Diseases, supported by post-marketing surveillance and nutraceuticals research. For pharmaceutical and biotech sponsors running late-phase clinical development programs.
• Biologics Services End-to-end biologics and biosimilar development support including PK/PD studies, immunogenicity and ADA/NAb assay services, cell and molecular biology, immunology, physicochemical characterization, and biosimilar comparability assessments. For biotech sponsors developing biosimilars, monoclonal antibodies, peptides, and other biomolecules.
• CDM, Biostatistics & Real World Evidence Clinical data management, biostatistics, and real-world evidence analytics encompassing claims database analysis, EHR curation, registry data studies, HEOR, epidemiology, and safety detection supporting regulatory submissions. For clinical trial sponsors needing data management, biostatistics, and real-world evidence analytics.
• Bioanalytical Laboratory Services Advanced bioanalytical testing powered by 21 LC-MS/MS systems (SCIEX API 6500+, 5500, 4500, 4000 and Waters Xevo TQ-XS/TQS/TQ), supporting 1,000+ validated analytical methods for multi-analyte, chiral, and endogenous substance quantification with regulatory-compliant method development and validation. For pharmaceutical and biotech sponsors needing bioanalytical method development, validation, and sample analysis.
• Biologics Laboratory Services Specialized biologics characterization laboratory equipped with Flow Cytometry (Attune), NGC Chromatography (Bio-Rad NGC Discover Quest 10 Plus), Nexera X2 UPLC/HPLC, ICP-OES, and ICP-MS for cell-based assays, protein characterization, immunogenicity testing, and purification of peptides, monoclonal antibodies, and biomolecules. For biotech sponsors requiring biologics characterization, immunogenicity, and biosimilar comparability.
• Pre-clinical Services Pre-clinical services initiated as a new extension of Accutest's CRO platform in 2023, complementing its BA/BE, clinical, bioanalytical, and biologics services.

Quantifiable outcome

• 98% Study Accuracy
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Pharmaron: China-headquartered CRO/CDMO with growing bioanalytical and biologics services. Emerging Asian competitor with cost-arbitrage model analogous to Accutest but with stronger biologics manufacturing footprint.
• Sai Life Sciences: India-based CRO/CDMO offering discovery, clinical, and bioanalytical services. Comparable in scale and Indian cost base, with growing biologics and complex molecule capabilities.

Direct peers

• Lambda Therapeutic Research: Indian CRO offering BA/BE, clinical, and bioanalytical services with multi-site Indian operations. Closest direct competitor given overlapping service portfolio, Indian footprint, and similar sponsor base.
• Cliantha Research: Indian full-service CRO with BA/BE, bioanalytical, clinical, and dermatology specialty services. Direct domestic competitor targeting the same global pharmaceutical sponsors with comparable regulatory inspection history.
• Veeda Clinical Research: India-based CRO with bioequivalence, clinical, and bioanalytical capabilities across multiple sites. Direct peer competing for generic and innovator pharma bioequivalence work.

Broad incumbents

• IQVIA: Global full-service CRO with end-to-end clinical, bioanalytical, and real-world evidence capabilities. Represents the top end of the sponsor-consolidation trend that mid-sized Indian CROs must contend with.
• Fortrea (formerly Labcorp Drug Development): Global CRO spun out of Labcorp with extensive early- and late-phase clinical and bioanalytical services. Large incumbent competing for the same global pharma master agreements.
• Syneos Health: Global biopharmaceutical solutions organization offering clinical development and bioanalytical services. Competes with Accutest for late-phase and bioanalytical work from global pharma sponsors.
• Parexel International: Global CRO with broad clinical, bioanalytical, and regulatory services. Large incumbent whose full-service model is the primary competitive threat for mid-tier CROs in global sponsor panels.
• WuXi AppTec: Global CRO/CDMO with extensive clinical, bioanalytical, and biologics capabilities from a China-based platform. Large incumbent expanding into global pharma services with comparable integrated model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/accutest_lab
• Facebookfacebook.com/Accutest-Research-Laboratories-927405063972897

Compliance16 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accutest